News•Feb 15, 2026
Carl Zeiss Meditec: When the Thesis Gets Punched in the Mouth
In this episode, the host revisits his deep‑dive analysis of Carl Zeiss Meditec, using the company’s Q1 FY2025/26 earnings call as a live case study to demonstrate how investment theses should evolve with new data. He critiques the common practice of publishing a static model and then silently updating it, arguing for a transparent, continuous dialogue between conviction and market evidence. The discussion highlights the importance of recalibrating assumptions—distinguishing between a flawed structural thesis and merely timing adjustments—while maintaining intellectual honesty. Listeners gain a practical framework for updating priors without abandoning core investment ideas.
